Kolabtree Releases Technical File Checklist for Medical Device Manufacturers

Kolabtree (an expert network) has announced the release of a new free resource for medical device manufacturers: The essential technical file checklist. Developed by regulatory experts, the checklist is aimed at medical device companies who want to place a device in the EU market and need to comply with MDR guidelines. It’s available to download for free here.

What is a technical file?

A technical file is a compilation of all the technical information about a medical device. This includes everything from the design of the product to how it’s manufactured and everything in between. It’s important to have a technical file because it provides essential information to regulators and helps ensure that medical devices are safe and effective. The technical file contains all the necessary documentation to support the regulatory submission, including test data, results, and analysis. It’s also used during post-market surveillance to help assess any safety issues that may arise with the device.

A technical file is a vital part of the EU MDR compliance process. In order to meet the requirements of the new regulation, medical device manufacturers must provide extensive technical documentation. This includes design and manufacturing files, technical specifications, user manuals, clinical evaluation reports, and more. Failure to submit a technical file can result in regulatory penalties, so it’s essential to make sure that your technical file is complete and accurate.

In order to make it easier for medical device manufacturers to comply with the EU MDR, Kolabtree has released a one-page technical file checklist. The checklist covers all of the essential components of a technical file, and helps you make sure that your documentation is complete and accurate. Kolabtree’s global network of medical device consultants offer services like medical writing, FDA/MDR compliance, data analysis, and more.

Download the Technical File checklist for free here

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”